Research Articles | Page 13 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria Aug 2023 Haematologica Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Jun 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria Jun 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes Sep 2019 Clinical Cancer Research: an official Journal of the American Association of Cancer Research Myelodysplastic Syndromes (MDS)
Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria Jun 2024 Blood Advances Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria Dec 2024 Expert Review of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Mar 2021 The New England Journal of Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)